Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Andre who wrote (20300)	4/6/1999 10:31:00 AM
From: Joe Fang	Respond to of 23519

VVUS just spiked on decent volume...hmm..

To: Andre who wrote (20300)	4/6/1999 10:38:00 AM
From: Joe Fang	Read Replies (2) \| Respond to of 23519

Has VVUS been halted too? I am not seeing trades go through in the last 10 mins... last trade 1000 at 3 7/8 @10:26am volume at 73.3k

To: Andre who wrote (20300)	4/6/1999 11:17:00 AM
From: OmertaSoldier	Respond to of 23519

read all about it. Tuesday April 6, 9:34 am Eastern Time Shareholders OK Astra-Zeneca Merger STOCKHOLM, Sweden (AP) -- Shareholders in Swedish drug-maker Astra have approved a merger with Britain's Zeneca, completing the moves to create one of the world's largest pharmaceutical companies, Astra and Zeneca said in a joint announcement Tuesday. A small bloc of Astra shareholders had been skeptical of the merger plans, which were announced in December. But the companies said the merger was accepted by shareholders with 96 percent of Astra's capital and votes. The companies said the redenomination of Zeneca's share capital into dollars was completed on Monday and the name of the group was changed to AstraZeneca PLC. AstraZeneca's headquarters will be in London, with research and development operations in Sweden. The company is expected have annual sales of about $11.5 billion. Astra's ulcer and heartburn medication Prilosec is the world's best-selling prescription drug. Zeneca is the second-leading maker of cancer drugs behind Bristol-Myers Squibb of the United States. It also has a large agrochemical business and owns Salick Health Care, a U.S. operator of cancer treatment and dialysis centers. Commenting on the formation of the new pharmaceutical group Tom McKillop, chief executive of AstraZeneca, said: ''I'm determined that the energy, thoroughness and cooperation which has enabled the new company to be created in such good time will now be devoted to ensuring that AstraZeneca builds further on its excellent platform for growth.''